Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bashir M. Mohamed has a total of 155 co-authors. Here are the top co-authors by number of shared publications:

  • Cara Martin

    Department of Histopathology, Trinity College Dublin, Dublin 8, Ireland; Trinity St James's Cancer Institute, Dublin 8, Ireland

    7 shared publications
  • Derek G. Doherty

    Trinity St James's Cancer Institute, Dublin 8, Ireland; Department of Immunology, Trinity College Dublin, Dublin 8, Ireland

    4 shared publications
  • Feras Abu Saadeh

    Trinity St James’s Cancer Institute, Dublin 8, Ireland

    4 shared publications
  • Stavros Selemidis

    School of Health and Biomedical Sciences, RMIT University, Bundoora, Vic, 3083, Australia

    4 shared publications
  • Mark Bates

    Department of Histopathology, Trinity College Dublin, Dublin 8, Ireland

    3 shared publications
  • Sharon O’ Toole

    Trinity College Dublin, Dublin, Ireland

    3 shared publications

Latest Publications

  • Open Access

    Lipid metabolism in γδ T-cell activation: Implications for immunotherapy in ovarian cancer

    by Karolina Stirblyte, Yazid Ghanem, Mark Bates, Steven G. Gray, Feras Abu Saadeh, Cara Martin, Sharon O'TOole, John J. O'LEary, Derek G. Doherty, Bashir M. Mohamed

  • Open Access

    Single-Cell Isolation and Patient-Derived Organoid Generation Using the Pala™ Single Cell Dispenser with Cancer Cell Lines Spiked into Blood as a Circulating Tumour Cell Model: A Platform for Precision Oncology and Drug Discovery

    by Shambhavi Krishna, Fatma Yaren Giray, Musha Yang, Karolina Stirblyte, Steven G. Gray, Feras Abu Saadeh, Marie Reidy, Cara Martin, Sharon O’TOole, Doug A. Brooks, et al.

    The isolation of cancer cells and rare circulating tumour cells (CTCs) and the initiation of patient-derived organoids (PDOs) represent two critical new approach methodologies (NAMs) for advancing precision oncology and drug discovery. However, current technologies encounter significant limitations, including high system pressures that compromise cell viability, sample loss, and reliance on marker-dependent enrichment strategies. Here, we performed a technical validation of the Pala™ Single Cell Sorter/Dispenser (Bio-Techne) using cancer cell lines spiked into healthy donor blood as a model for CTCs, alongside cells isolated from ovarian cancer (OC) patients and cervical cancer cell lines. The platform achieved up to 80% single-cell dispensing efficiency under gentle sorting conditions (<2 psi), successfully dispensing single cancer cells, cell clusters, and cancer cells spiked into blood (mimicking CTCs). Concurrently, three-dimensional organoid structures generated from dissociated OC samples and cervical cancer cell lines showed viable growth and cluster formation within one week. Compared to literature values for fluorescence-activated cell sorting (FACS), the Pala™ maintained higher post-sort viability (88% vs. 55-70%) and organoid initiation efficiency (68% vs. 42%). This work establishes the Pala™ as a flexible tool for patient cancer cell dispensing, CTC-mimic isolation, and PDO generation within drug discovery workflows. Clinical validation using authentic patient CTCs remains necessary prior to clinical implementation.

  • Open Access

    Nanoparticle-mediated delivery of PD-L1 inhibitor enhances γδ T cell immunotherapy against metastatic ovarian cancer cells

    by Laura O’COnner, Jessica Eakins, Mark Bates, Ola Ibrahim, Cara Martin, Victoria Malone, Steven G. Gray, Feras Abu Saadeh, Hassan Rajab, Doug A. Brooks, et al.

    Introduction: Immune checkpoint inhibitors (ICIs) have only shown limited efficacy for patients with ovarian cancer (OC), partly due to the immune suppressive tumour microenvironment (TME) and platelet cloaking of the cancer cells. We tested a nanomedicine strategy to enhance γδ T cell immunotherapy by conjugating the PD-L1 inhibitor (BMS202) to nanodiamonds (NDs). Methods: Patient-derived ascites cells were exposed to activated platelets to model platelet cloaking and the immunosuppressive phenotype in metastatic OC. ND/BMS202 nanocomplexes were then applied to platelet-conditioned OC cells and co-cultured with expanded γδ T cells. Cytotoxicity and immune activation were assessed by quantifying Granzyme B, CD107a, γ-H2AX, cleaved caspase-3, and cleaved caspase-8. Results: ND-mediated delivery of BMS202 significantly enhanced γδ T cell-mediated killing of platelet cloaked OC cells in a dose-dependent manner, with greater efficacy than free BMS202 This enhanced cytotoxicity was supported by increased degranulation (CD107a), Granzyme B release, tumour cell apoptosis (caspase cleavage) and DNA damage (γ-H2AX staining). Conclusions: ND-based delivery of the PD-L1 inhibitor (BMS202) enhances γδ T cell-mediated killing of platelet-cloaked metastatic OC cells. While our data support enhanced γδ T cell cytotoxicity following BMS202 delivery, direct evidence of PD-L1 target engagement or PD-1/PD-L1 binding inhibition was not demonstrated in this study. These findings nonetheless justify further validation in patient-derived organoid models to optimize this γδ T cell-based combination immunotherapy and advance its development as a precision therapeutic strategy for metastatic OC.

  • Open Access

    An Analysis of G3BP2 in Non-Small Cell Lung Cancer

    by Leela S. S. Bandi, Leah Timon, Elena O’Toole, Diarmuid O’Connor, Kristen Andersen, Bashir M. Mohamed, Siobhan Nicholson, Gerard J. Fitzmaurice, Ronan Ryan, Vincent Young, et al.

    Background/Objectives: Cancer cells are subjected to various stress conditions and have stress adaptability strategies to survive. Various types of stresses lead to the aggregation of cytoplasmic RNA granules known as stress granules (SGs), seen in normal and tumor cells, and aid in cell survival by avoiding cell apoptosis. G3BP stress granule assembly factor 2 (G3BP2) encodes a multifunctional protein with known roles as a critical component of SGs and is also associated with chemoresistance in cancer, but its known roles in non-small cell cancer (NSCLC) are limited. Methods: We evaluated the expression of G3BP2 via qPCR and immunohistochemistry on a retrospective cohort of NSCLC isolated at surgery in St James’s Hospital, Dublin, Ireland. Expression levels were correlated with clinicopathological parameters. Survival analyses, including Kaplan–Meier analyses, were used to determine the prognostic value. Additional correlations with other available NSCLC datasets were explored. Results: In contrast to other studies, we did not observe upregulated expression of G3BP2. Furthermore, Kaplan–Meier analyses did not identify any prognostic value associated with G3BP2 expression in patient tissues in contrast to other published data. Bioinformatic analyses on these other datasets found strong correlations between G3BP2 and core stress granule genes in NSCLC. Additional analyses also identified correlations between G3BP2 expression and immune cell infiltration, immune cell exhaustion, and DNA Damage Response pathways. An examination of the available datasets did not find any overall prognostic value for altered DNA methylation and survival. However, two individual CpG residues were identified for which higher methylation was associated with worse overall survival. Finally, the effects of a G3BP2 inhibitor on cellular proliferation were assessed. Conclusions: In our analysis, G3BP2 was not associated with survival benefit. However, clear associations were observed between altered expression of this gene and a number of important pathways linked to cancer pathogenesis, and further studies are warranted to assess this gene (and/or) stress granules in cancer.

  • Open Access

    Clove Aqueous Extract Triggers a Multi-Organellar Stress Crisis through Lysosomal Destabilisation and Mitochondrial Hyperpolarisation to Suppress Patient-Derived Ovarian Cancer Cells

    by Yazid Ghanem, Hadeel Odwan, Musha Yang, Victoria Malone, Fawza Alenazi, Fears Abu Saadeh, Steven G. Gray, Derek Doherty, Cara Martin, Sharon O’toole, et al.

    Ovarian cancer (OC) remains a lethal malignancy with limited therapeutic options, underscoring the need for the identification of novel agents. Natural products like clove ( Syzygium aromaticum ) have shown promising anti-cancer activity, but their mechanism in OC is poorly understood. This study investigates the anti-tumour effects and underlying mechanisms of a clove aqueous extract (CAE) on a panel of patient-derived OC cells. We found that CAE significantly inhibited cellular proliferation and induced cell death in a time-and dose-dependent manner. Mechanistically, CAE induced profound cellular stress, activating the transcription factor ATF-2. This was accompanied by a significantly increased lysosomal stress response, as evidenced by increased lysosomal mass/acidity, and a pathogenic hyperpolarisation of the mitochondrial membrane potential (ΔΨm). The bioenergetic crisis induced as a consequence resulted in a sharp reduction in cellular oxygen consumption rate (OCR). Notably, the sensitivity to CAE-induced lysosomal and mitochondrial dysfunction varied across cell lines, revealing distinct phenotypic responses. Our results demonstrate that clove extract exerts its anti-tumour effects by orchestrating a multi-organellar stress response, positioning lysosomal disruption as a central event in its mechanism of action. This study provides a strong rationale for the further development of clove-based interventions for OC.


  • Open Access

    Proof of concept nanotechnological approach to in vitro targeting of malignant melanoma for enhanced immune checkpoint inhibition

    by Bandar Alharbi, Husam Qanash, Naif K. Binsaleh, Salem Alharthi, Abdulbaset M. Elasbali, Chandranil H. Gharekhan, Muhammad Mahmoud, Emmanouil Lioudakis, John J. O’lEary, Derek G. Doherty, et al.

    Immunotherapies, including immune checkpoint inhibitors, have limitations in their effective treatment of malignancies. The immunosuppressive environment associated with the tumor microenvironment may prevent the achievement of optimal outcomes for immune checkpoint inhibitors alone, and nanotechnology-based platforms for delivery of immunotherapeutic agents are increasingly being investigated for their potential to improve the efficacy of immune checkpoint blockade therapy. In this manuscript, nanoparticles were designed with appropriate size and surface characteristics to enhance their retention of payload so that they can transmit their loaded drugs to the tumor. We aimed to enhance immune cell stimulation by a small molecule inhibitor of PD-1/PD-L1 (BMS202) using nanodiamonds (ND). Melanoma cells with different disease stages were exposed to bare NDs, BMS202-NDs or BMS202 alone for 6 h. Following this, melanoma cells were co-cultured with freshly isolated human peripheral blood mononuclear cells (hPBMCs). The effects of this treatment combination on melanoma cells were examined on several biological parameters including cell viability, cell membrane damage, lysosomal mass/pH changes and expression of γHA2X, and caspase 3. Exposing melanoma cells to BMS202-NDs led to a stronger than normal interaction between the hPBMCs and the melanoma cells, with significant anti-proliferative effects. We therefore conclude that melanoma therapy has the potential to be enhanced by non-classical T-cell Immune responses via immune checkpoint inhibitors delivered by nanodiamonds-based nanoparticles.


  • Open Access

    Ex vivo expansion of circulating tumour cells (CTCs)

    by Bashir M. Mohamed, Mark P. Ward, Mark Bates, Cathy D. Spillane, Tanya Kelly, Cara Martin, Michael Gallagher, Sheena Heffernan, Lucy Norris, John Kennedy, et al.

    Circulating tumour cells (CTCs) are a critical intermediate step in the process of cancer metastasis. The reliability of CTC isolation/purification has limited both the potential to report on metastatic progression and the development of CTCs as targets for therapeutic intervention. Here we report a new methodology, which optimises the culture conditions for CTCs using primary cancer cells as a model system. We exploited the known biology that CTCs thrive in hypoxic conditions, with their survival and proliferation being reliant on the activation of hypoxia-inducible factor 1 alpha (HIF-1α). We isolated epithelial-like and quasi-mesenchymal CTC phenotypes from the blood of a cancer patient and successfully cultured these cells for more than 8 weeks. The presence of CTC clusters was required to establish and maintain long-term cultures. This novel methodology for the long-term culture of CTCs will aid in the development of downstream applications, including CTC theranostics.


  • Open Access

    Aberrant protein expression of Appl1, Sortilin and Syndecan-1 during the biological progression of prostate cancer

    by Carmela Martini, Jessica M Logan, Alexandra Sorvina, Colin Gordon, Andrew R Beck, Ben S-Y Ung, Maria C Caruso, Courtney Moore, Ashleigh Hocking, Ian R D Johnson, et al.


  • Open Access

    Ex Vivo Expansion of Circulating Tumour Cells (CTCs)

    by Bashir Mohamed, Mark Ward, Mark Bates, Cathy Spillane, Tanya Kelly, Cara Martin, Michael Gallagher, Sheena Heffernan, Lucy Norris, John Kennedy, et al.

    Circulating tumour cells (CTCs) are a critical intermediate step in the process of cancer metastasis. The reliability of CTC isolation/purification has limited both the potential to report on metastatic progression and the development of CTCs as targets for therapeutic intervention. Here we report a new methodology, which optimises the culture conditions for CTCs using primary cancer cells as a model system. We exploited the known biology that CTCs thrive in hypoxic conditions, with their survival and proliferation being reliant on the activation of hypoxia-inducible factor 1 alpha (HIF-1α). We isolated epithelial-like and quasi-mesenchymal CTC phenotypes from the blood of a cancer patient and successfully cultured these cells for more than eight weeks. The presence of CTC clusters was required to establish and maintain long-term cultures. This novel methodology for the long-term culture of CTCs will aid in the development of downstream applications, including CTC theranostics.

  • Adaptation of a Cell-Based High Content Screening System for the In-Depth Analysis of Celiac Biopsy Tissue

    by Sarah E. J. Cooper, Bashir M. Mohamed, Louise Elliott, Anthony Mitchell Davies, Conleth F. Feighery, Jacinta Kelly, Jean Dunne

    The IN Cell Analyzer 1000 possesses several distinguishing features that make it a valuable tool in research today. This fully automated high content screening (HCS) system introduced quantitative fluorescent microscopy with computerized image analysis for use in cell-based analysis. Previous studies have focused on live cell assays, where it has proven to be a powerful and robust method capable of providing reproducible, quantitative data. Using HCS as a tool to investigate antigen expression in duodenal biopsies, we developed a novel approach to tissue positioning and mapping. We adapted IN Cell Analyzer 1000’s image acquisition and analysis software for the investigation of tissue transglutaminase (tTG) and smooth muscle alpha-actin (SM α-actin) staining in paraffin-embedded duodenal tissue sections from celiac patients and healthy controls. These innovations allowed a quantitative analysis of cellular structure and protein expression. The results from routine biopsy material indicated the intensity of protein expression was altered in celiac disease compared to normal biopsy material.